Differences among available immunoglobulin preparations for intravenous use.

Area of Science:

• Immunology
• Biotechnology
• Pharmacology

Background:

• Intravenous immunoglobulin (IVIG) preparations are crucial therapeutics.
• Current IVIG products meet basic intravenous administration requirements.
• Manufacturing processes lead to significant variations in IVIG preparations.

Purpose of the Study:

• To analyze the impact of different manufacturing methods on IVIG preparations.
• To compare the properties of enzymatically treated, chemically modified, and anion-exchange purified IVIG.
• To evaluate the subclass composition and functional characteristics of various IVIG products.

Main Methods:

• Comparative analysis of IVIG preparations based on manufacturing techniques.
• Assessment of IgG subclass composition (IgG1, IgG2, IgG3, IgG4).
• Evaluation of Fc-related functions, including Fc receptor interaction and phagocytosis-promoting activity.

Main Results:

• Enzymatic treatment (pepsin, plasmin) reduces half-life and alters IgG subclass distribution.
• Chemical modifications (beta-propiolactone) result in loss of IgG3 and altered Fc functions.
• Anion-exchange purification leads to reduced IgG4 levels.
• Non-modified US-marketed IVIGs (Gamimune N, Gammagard, Sandoglobulin) exhibit similar functional properties, except for IgG subclass representation.
• No elevated levels of contaminants like prekallikrein activator or irregular anti-erythrocyte antibodies were found in these preparations.

Conclusions:

• Manufacturing methods significantly influence IVIG properties, particularly IgG subclass composition and function.
• Understanding these differences is critical for selecting appropriate IVIG products for specific therapeutic needs.
• Non-modified IVIG preparations generally maintain desirable functional characteristics, but subclass profiles vary.